Pembrolizumab new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression, according to the results of the phase III KEYNOTE-024 trial.